Who will renew the KEY hydroxychloroquine
The world health organization intends to resume clinical investigation of anti-malarial drug hydroxychloroquine as a means of therapy COVID-19. A study conducted by who was suspended for security reasons in may of this year after patients treated with hydroxychloroquine, was recorded an increased mortality rate and complications associated with cardiac arrhythmias.
However, during the online conference held on Wednesday in the United States, who Director-General Tedros Aden Gebreyesus said that experts from the international organization recommend to finish all the investigation of potential means of treatment of coronavirus infection, including antimalarial drugs.
The decision of the who, adopted in may, influenced the course of other KEY hydroxychloroquine. In particular, at the end of may on the suspension of recruitment of volunteers for their own studies of the drug, said the company Sanofi.
Deputy Director General of who Sumia Swaminathan (Swaminathan Soumya) said that all studies of the drug should continue. “Our commitment to our patients is to get a definite answer, it works this medicine”, she explained.
Swaminathan also announced the intention of the who to see the results of clinical studies of the drug Aviewer (favipiravir), which was recently approved for use as treatment COVID-19 in Russia.
